The rating assignment is based on Dana-Farber’s strong working partnerships with other academic institutions and prominent market position in the field of cancer research and treatment.
The outlook is stable, reflecting Moody’s Investors Service’s expectation that Dana-Farber will continue to translate its leading reputation in cancer research into strong revenue and resource growth.
Moody’s Investors Service has also affirmed the “A1” ratings on Dana-Farber’s $233 million of outstanding revenue bonds.
More articles on healthcare finance:
Craneware, OhioHealth to present on pharmacy revenue integrity HFMA’s Annual National Institute
NJ owes counties $37M in Medicaid repayments
Moody’s affirms Flagler Hospital’s ‘A3’ rating
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
